이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Safety and Acceptability of PRO 2000 Vaginal Gel in HIV Uninfected Women in India

Phase I Safety and Acceptability Study of the Investigational Vaginal Microbicide PRO 2000/5 Gel (P)

PRO 2000 Gel is designed to be inserted into the vagina to protect women from getting HIV during sex. So far, PRO 2000 Gel has been tested for safety in 136 women from Europe and the United States. This study will evaluate the safety and acceptability of PRO 2000 Gel when used by women in Pune, India. The study will also examine what Indian women and men think about using PRO 2000 Gel.

연구 개요

상태

완전한

정황

상세 설명

Topical microbicides are designed to prevent the sexual transmission of HIV and other disease pathogens. PRO 2000/5 Gel (P), or PRO 2000, is a vaginal microbicide that has been evaluated in Phase I safety trials in Europe and the U.S. PRO 2000 Gel is easily manufactured, highly stable, and highly water-soluble. The aqueous gel formulation contains a synthetic carbomer, a lactic acid/lactate buffer, and preservatives. In vitro, PRO 2000 Gel has been shown to suppress infection by herpes viruses, Chlamydia trachomatis, Neisseria gonorrhoeae, and a wide range of HIV-1 isolates. This study will evaluate the safety and acceptability of PRO 2000 Gel in HIV uninfected women in Pune, India. The study is a precursor to a larger Phase II/III study of PRO 2000 Gel.

Participants in this study will be sexually active HIV uninfected women at either low or high risk for HIV infection. Male partners of these women will also be enrolled in the study. Participants will be asked to apply PRO 2000 Gel twice a day for 14 consecutive days between menses and to have vaginal intercourse with a single male partner, using study-provided male condoms, at least twice per week during the two weeks of PRO 2000 Gel use. Participants will have a screening visit, an enrollment visit, and 3 study visits during the two weeks of PRO 2000 Gel use; each visit will last about 1 hour. Study visits will include a medical history, gynecologic exam, blood and urine tests, and product acceptability questionnaires. Colposcopy will be performed three times during the study. Participants will also be asked to complete a Daily Study Record about product use and sexual activity and questionnaires about their willingness to use the product and their perceptions of the product.

Four weeks after using PRO 2000 Gel, participants will be asked to participate in a focus group to discuss product acceptability. Participants' male partners will also be asked to participate in focus groups about product use.

연구 유형

중재적

등록

120

단계

  • 1단계

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria for All Female Participants:

  • Age 18 to 45
  • HIV uninfected
  • Regular menstrual cycle of at least 21 days or no menstrual cycle because of long-acting progestin use
  • No change in hormonal contraceptive use in the 3 months prior to study entry
  • Agree to use acceptable methods of contraception during the study
  • Normal Pap smear at screening or in the 3 months prior to study entry
  • Sexually active with a single male sexual partner who is eligible for the study
  • Agree to abstain from sexual intercourse for 48 hours before the enrollment visit
  • Willing to complete Daily Study Records
  • Agree to follow study directions about PRO 2000 Gel use and sexual activity during the study

Additional Inclusion Criteria for Female Participants at Higher Risk for HIV Infection:

  • Sexually transmitted disease (STD) in the 3 months prior to study entry
  • Current male partner has had an STD in the 3 months prior to study entry

Inclusion Criteria for Male Partners of Female Participants:

  • Age 18 years or older
  • HIV uninfected
  • No STD symptoms at study entry
  • Agree to abstain from sexual intercourse for 48 hours before the enrollment visit
  • Agree to have vaginal intercourse only with partner who is taking part in the study
  • Agree to have vaginal intercourse at least twice a week while in the study and to use study provided male condoms

Exclusion Criteria for All Female Participants:

  • Menopausal
  • Breastfeeding
  • Used non-therapeutic intravenous drugs within 1 year of study
  • Currently pregnant or have been pregnant in the 3 months prior to study entry
  • Serious liver, kidney, or blood abnormalities
  • Urinary tract infection as determined by positive urine culture
  • Genital abnormality
  • History of adverse reaction to anticoagulants
  • History of sensitivity or allergy to latex
  • Used any spermicide or spermicidally lubricated condom in the week prior to study entry
  • Participated in any investigational drug trial in 30 days prior to study entry
  • Used an intrauterine contraceptive device in the 3 months prior to study entry
  • Abnormal Pap smear in the 3 months prior to study entry
  • Gynecological surgery in the 3 months prior to study entry
  • Breakthrough menstrual bleeding in the 3 months prior to study entry
  • Vaginal bleeding during or following intercourse in the 3 months prior to study entry

Additional Exclusion Criteria for Female Participants at Low Risk for HIV Infection:

  • STD or pelvic inflammatory disease in the 3 months prior to study entry
  • Current male partner has had an STD in the 3 months prior to study entry
  • Current male partner has injected non-therapeutic drugs in the 3 months prior to study entry
  • Signs on pelvic exam consistent with an STD other than bacterial vaginosis

Exclusion Criteria for Male Partners of Female Participants

  • History of adverse reaction to latex
  • Refuse examination or treatment for an STD or STD symptoms

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: Smita N. Joshi, MBBS, National AIDS Research Institute (Pune, India)
  • 연구 의자: Steven J. Reynolds, MD, FRCP(C), Johns Hopkins University Department of Medicine

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 등록 날짜

최초 제출

2004년 4월 16일

QC 기준을 충족하는 최초 제출

2004년 4월 16일

처음 게시됨 (추정)

2004년 4월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2009년 12월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2009년 12월 22일

마지막으로 확인됨

2006년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다